Clinical Trial Update: Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the efficacy and safety of early convalescent plasma collected from COVID-19 patients in individuals admitted with COVID-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome Coronavirus 2 Infection

Drugs mentioned

• Convalescent Plasma (convalescent plasma)

Snippet

Sponsor: Pontificia Universidad Catolica de Chile | Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 | Phase 2 | Status: COMPLETED